Publications found:
32,992
Sort by:
Investigation Report on China Aripiprazole Market, 2009-2018
US$ 1,800.00
... the end of 2013 there have been over 10 million schizophrenia patients in China, and the number is still increasing year after year. Schizophrenia ... in Different Dosage Forms in China Hospital Market Prospect of China Aripiprazole Market The following enterprises and people are recommended to purchase this ...
March 2014
40 pages
HIV Vaccine Market Opportunity & Clinical Pipeline Analysis
US$ 2,000.00
... promising. “HIV Vaccine Market Opportunity & Clinical Pipeline Analysis” Report Highlights: Introduction to HIV Vaccine & Mechanism Global HIV Incidence Scenario R&D Funding Scenario for HIV Vaccine FDA Regulatory Framework HIV Vaccine Clinical Trial by Phase & Country HIV Vaccines in Development Phase ...
March 2014
330 pages
Investigation Report on China Enoxaparin Sodium Market, 2009-2018
US$ 1,800.00
... , and treat unstable angina and non-Q-wave myocardial infarction. Enoxaparin sodium generic drugs produced by Sandoz and Amphastar Pharm have ... Market Production Status of Enoxaparin Sodium Generic Drug in China Major Enoxaparin Sodium Manufacturers in China Prospect of China Enoxaparin Sodium Market The ...
February 2014
40 pages
Investigation Report on China Pemetrexed Market, 2009-2018
US$ 1,800.00
... value keeps increasing year after year. The CAGR of sales value of pemetrexed was 50.6% from 2004 to 2011. The sales value was only ... China Hospital Market Incidence of Cancer in China Manufacturing Schedule of Pemetrexed generic drug Prospect of China Pemetrexed Market The following enterprises and people ...
February 2014
40 pages
Indonesia Pharmaceuticals Industry Report - H2, 2013
US$ 475.00
... for this low figure. Hence, immense potential exists for growth in Indonesia’s pharmaceutical sector. However, the sector is often plagued by regulatory flip- ... 2012, a single physician served 4,900 citizens in the country. The government of Indonesia has targeted to bring down this figure to 2,500 at the end ...
February 2014
31 pages
Vitamin Price in China
US$ 2,979.00
... benchmarking research studying the cost structure of Chinese vitamin C and the competitiveness of major Chinese players. ... set up the model and verify afterwards. The breakeven price of Chinese products is concluded. The aim of ... as how to penetrate the ever-increasing China market and how to catch the maximum ...
February 2014
6 pages
Investigation Report on China Bevacizumab Market, 2009-2018
US$ 1,800.00
... remedy. Public data shows that the global sales value of bevacizumab in 2012 exceeded USD 6.3 billion, ranking the fourth among the ... Dosage Forms in Hospital Market in China Incidence of Cancer in China Manufacturing Schedule of Bevacizumab generic drug Prospect of China Bevacizumab Market The author ...
February 2014
40 pages
Investigation Report on China Duloxetine Market, 2009-2018
US$ 1,800.00
... increasing, which nearly reached USD 5 billion in 2012. The success of duloxetine sales also comes from its persistent exploration and study ... in Different Dosage Forms in China Hospital Market Prospect of China Duloxetine Market The author recommends the report to the following: Antidepressant APIs ...
February 2014
40 pages
Value-driven Pharma: Integrating health outcomes across the product lifecycle
US$ 595.00
... pharma companies truly integrating health outcome values into product development or merely paying lip-service? In a rare and comprehensive insight into thriving in the "Outcomes Era", Value-driven Pharma: Integrating health outcomes across ... been shaped by economics. In Value-driven Pharma: Integrating health outcomes across the product lifecycle, you will: Understand the importance of endorsing a comprehensive approach to health outcomes from the earliest ...
February 2014
44 pages
Stakeholder Perspectives: Innovation within the Biopharma Industry
US$ 2,495.00
... all of the ‘low hanging fruit’ have been taken there is another perspective: that there is plenty of fruit left on the tree and companies ... company, patient advocacy group or regulatory body, this report Stakeholder Perspectives: Innovation within the Biopharma Industry provides a thought provoking assessment ...
February 2014
99 pages
Investigation Report on China Valsartan Market, 2009-2018
US$ 1,800.00
... can acquire the following information: Market Share of Major Valsartan Manufacturers in Sampling Hospitals in China Sales price of valsartan in hospital market in China Major valsartan enterprises in China Market share of valsartan by dosage form in hospital market in China Prospect of China valsartan ...
February 2014
40 pages
India Pharmaceutical Industry Report - H2, 2013
US$ 475.00
... China, Japan, and the United States. Over the last decade, India’s pharmaceutical and health care sector has made great strides. ... and health care sector witnessed a challenging period in 2013. The domestic pharmaceutical market grew by 9% in 2013, having grown by 12% in 2012. The notification of Drug Prices ...
February 2014
37 pages
Europe Orphan Drug Market Outlook 2018
US$ 1,200.00
... orphan drugs. “Europe Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to Europe orphan drug market: Europe Orphan Drug Market Overview Orphan Drug Designation Criteria Market Specific Reimbursement Policy & Regulatory Framework Europe ...
February 2014
134 pages
US Orphan Drug Market Outlook 2018
US$ 1,200.00
... . “US Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to US orphan drug market: US Orphan Drug Market Overview Orphan Drug Designation Criteria Market Specific Reimbursement Policy & Regulatory Framework US Orphan Drug ...
February 2014
160 pages
Global Radiopharmaceuticals Market Insight
US$ 2,200.00
... . “Global Radiopharmaceuticals Market Insight” Report Highlights Global Radio Pharmaceuticals Market Overview by Region arget Patient Base by Region Radiopharmaceuticals Market Regulation for US, Europe & Canada Radioisotopes Used in Radiopharmaceuticals Radiopharmaceutical Clinical Pipeline Insight ...
February 2014
450 pages
The US Specialty Pharmaceutical Market Report: 2013 Edition
US$ 800.00
... that address the unmet need of the patients as the specialty pharmaceutical market has the ability to sustain the high cost of these ... sluggish pace of innovation and inappropriate use of therapeutic drugs. The specialty pharmaceutical market witnesses fierce competition with numerous top notch players; such ...
January 2014
77 pages
China Pharmaceuticals Industry Report - H2, 2013
US$ 475.00
This report reviews the current trends and market outlook in China’s pharmaceuticals and health care industry. It also discusses the stock ... rural areas is trending up. Nevertheless, public health care expenditure as percentage of total GDP in China still trails many developed economies like the United States, ...
January 2014
34 pages
Global Trends and Developments in Enzymes
US$ 2,000.00
... product categories in which enzymes are used, regional analysis and opportunities for future growth of enzymes. Euromonitor International's Global Trends and Developments in Enzymes global briefing offers a comprehensive guide to the Ingredients market at an international level. It highlights the major ...
January 2014
45 pages
Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis
US$ 2,873.00
... Pipeline Analysis The report entitled Antibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis published in January 2014 is based on the evaluation of more ... arising from new site-specific and from polymer/nanoparticel-based conjugation systems and the most promising new payloads for ADCs. ...
January 2014
347 pages
Global Pharmaceutical and Biotechnology Outlook 2014 - Japan Pharma
US$ 2,500.00
... : NHI price cut, Japan generic opportunity, Prograf, Xtandi, Isavuconazole, Myrbetriq, Astellas, Chugai, Actemra, Perjeta, biosimilar, Kadcyla, breast cancer, prostate cancer, MPDL3280A, Daiichi Sankyo, Edoxaban , Ranbaxy, Dainnipon Sumitomo, Dainnipon, cancer stem cell inhibitor, BBI-608, Latuda, DS-3025 ...
January 2014
141 pages
Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU
US$ 2,500.00
... melanoma and breast cancer from major pharmaceutical companies. Many of them are ... high premium in speculation of getting acquired (ex. Roche-Alexion). Going forward, Economies of Scale will ... repurchase program and dividend policy. Global Biopharmaceutical Outlook 2014-Global Pharma, released by MP Advisors ...
January 2014
113 pages
World Drugs of Abuse Testing Market: Emerging Tests, Technology Assessment, Instrumentation Review, Market Shares, Sales Forecasts, and Strategic Profiles, of Key Players
US$ 6,800.00
... start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace ... , controls, calibrators and others. “2014 Analysis of the Global Drugs of Abuse Testing Market” is a unique study designed to help current suppliers and ...
January 2014
318 pages
Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech
US$ 2,500.00
... : Acorda, Alexion, Amgen, Biogen Idec, Celgene, Gilead, Regeneron, Vertex, ACOR, ALXN, AMGN, BIIB, CELG, GILD, REGN, VRTX, Soliris, Eculizumab, Asfotase alfa, Onyx, Kyprolis, RRMM, Denosumab, Prolia, XGEVA, Enbrel, Neupogen/ Neulasta, Biosimilar, Ampyra, Multiple Sclerosis, TECFIDERA, BG-12, PLEGRIDY, Gazyva ...
January 2014
145 pages
Europe Alzheimer's Disease Drug Pipeline Analysis
US$ 1,500.00
... / Originator/ Licensee/Collaborator Administrative Route Drug Class ATC Codes Europe Alzheimer’s Disease Drug Pipeline by Clinical Phase: Research: 19 Preclinical: 49 Clinical: 1 Phase-I: 25 Phase-I/II: 2 Phase-II: 26 Phase-II/III: 2 Phase-III: 5 Preregistration: 2 Marketed: 10 Unknown: 1
January 2014
265 pages
US Cancer Vaccine Pipeline Analysis
US$ 1,500.00
... for entry. Constituting almost 50% of the global pie, the US cancer vaccine market was estimated to be worth USD 14 Billion in 2012. With close ... cancer every year, this market is expected to o reach USD 20 billion by 2020. “US Cancer Vaccine Pipeline Analysis” by PNS Pharma gives comprehensive insight on the ...
January 2014
300 pages
Europe Parkinson’s Disease Drug Pipeline Analysis
US$ 1,000.00
... for Clinical Trial Owner / Originator/ Licensee/Collaborator Administrative Route Drug Class ATC Codes Europe Parkinson’s Disease Drug Pipeline by Clinical Phase: Research: 12 Clinical: 26 Phase-I: 14 Phase-I/II: 2 Phase-II: 6 Phase-II/III: 1 Phase-III: 3 Preregistration: 1 Marketed: 18
January 2014
199 pages
US Skin Cancer Drug Pipeline Analysis
US$ 1,200.00
... Trial Owner / Originator/ Licensee/Collaborator Administrative Route Drug Class ATC Codes Number of Skin Cancer Drug in Pipeline by Clinical Phase: Research: 3 Preclinical: 29 Clinical: 5 Phase 0: 1 Phase-I: 29 Phase-I/II: 18 Phase-II: 41 Phase-III: 13 Registered: 4 Marketed: 18 Unknown: 1
January 2014
310 pages
Japan Cancer Drug Pipeline Analysis
US$ 1,500.00
... for the pharma companies in their every-day decision making. “Japan Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ... to identify and analyze the available investment opportunity in the Japan cancer drug market based upon development process. Following parameters for ...
January 2014
557 pages
Europe Lung Cancer Drug Pipeline Analysis
US$ 1,200.00
... identify and analyze the available investment opportunity in the Europe lung cancer drug market based upon development process. Following parameters for ... drug profile in development phase are covered in “Europe Lung Cancer Drug Pipeline Analysis” research report: Drug Profile Overview Alternate Names for ...
January 2014
340 pages
Europe Orphan Drug Pipeline Analysis 2014
US$ 2,400.00
... in the Europe orphan designated drug market based upon development process. Following parameters for each drug profile in development phase are covered in “Europe Orphan Drug Pipeline Analysis 2014” research report: Drug Profile Overview Active Indication ...
January 2014
1430 pages
Global Vaccine Market Pipeline Analysis
US$ 1,500.00
... sub-divided into four groups namely, pediatrics, adolescents, adults and elderly. Though the vaccines segment forms a very small portion of the ... market is expected to surpass estimated USD 100 billion by 2025. “Global Vaccine Market Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ...
January 2014
1150 pages
Designing Clinical Trials to Show Value
US$ 595.00
... is changing. In Designing Clinical Trials to Show Value, you will: Understand how new concepts of value created by cost-conscious healthcare stakeholders are transforming clinical development programmes ... Understand new trends in clinical trials that promise to deliver product value sought by regulators, health systems and patients Designing Clinical Trials to Show Value answers key questions ...
December 2013
63 pages
Personalizing Cancer Drugs Trends: Market Research Report
US$ 1,450.00
... pace of growth is not being reported in the area of development of drugs and therapies for treating cancers. The report also predicts that the ... analysis in the diagnosis and treatment of various types of cancer, clearing the path for personalized medicine towards becoming a common expression associated with ...
December 2013
28 pages
2014 U.S. Pharmaceutical Preparation Mfg. Industry-Capital & Expenses Report
US$ 149.00
The 2014 U.S. Pharmaceutical Preparation Mfg. Industry-Capital & Expenses Report, published annually by Barnes Reports, contains timely and accurage industry statistics, forecasts and demographics. The report features 2014 current and 2015 forecast estimates on the cost of materials, capital expenditures, ...
December 2013
87 pages
2014 U.S. Pharmacies & Drug Stores Industry-Capital & Expenses Report
US$ 149.00
The 2014 U.S. Pharmacies & Drug Stores Industry-Capital & Expenses Report, published annually by Barnes Reports, contains timely and accurage industry statistics, forecasts and demographics. The report features 2014 current and 2015 forecast estimates on the cost of materials, capital expenditures, ...
December 2013
231 pages
Global and China Insulin Industry Report, 2013-2017
US$ 1,900.00
... Lilly, of which, Novo Nordisk accounted for 60.3% in 2012. While in recombinant human insulin market segments, the local Chinese enterprise –Tonghua Dongbao Pharmaceutical ... also received clinical approval issued by SFDA in September 2013. Global and China Insulin Industry Report, 2013-2017 mainly covers the ...
December 2013
80 pages
2014 Opportunities in the UK Therapeutic Drug Monitoring (TDM) Market
US$ 1,960.00
... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...
December 2013
247 pages
2014 Opportunities in the US Therapeutic Drug Monitoring (TDM) Market
US$ 2,800.00
... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...
December 2013
249 pages
2014 Opportunities in the Spanish Drugs of Abuse Testing Market
US$ 1,960.00
... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...
December 2013
260 pages
2014 Opportunities in the UK Drugs of Abuse Testing Market
US$ 1,960.00
... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...
December 2013
260 pages
2014 Opportunities in the US Drugs of Abuse Testing Market
US$ 2,800.00
... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...
December 2013
262 pages
2014 Opportunities in the European Drugs of Abuse Testing Market
US$ 5,200.00
This new 300-page report from Venture Planning Group provides a comprehensive analysis of the European drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales ...
December 2013
300 pages